Lutein and Alzheimer's Disease Study (LAD)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00596024 |
Recruitment Status :
Terminated
(Lack of enrollment)
First Posted : January 16, 2008
Last Update Posted : August 12, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Oxidative damage by free radicals may be involved in causing Alzheimer's disease (AD). Free radicals may lead to death of nerve cells and decline in brain function. Certain antioxidants may suppress this free radical damage associated with AD. Carotenoids are a family of naturally occurring antioxidants that have important functions for human health. Carotenoids are known to reduce oxidative damage, but their effects have not been studied in AD patients.
The objective of the study is to examine whether lutein supplementation helps to reduce oxidative damage from free radicals in AD patients.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Alzheimer's Disease | Dietary Supplement: lutein/zeaxanthin Dietary Supplement: placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 3 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Lutein and Oxidative Stress in Alzheimer's Disease - A Pilot Study |
Study Start Date : | December 2007 |
Actual Primary Completion Date : | July 2009 |
Actual Study Completion Date : | July 2009 |

Arm | Intervention/treatment |
---|---|
Experimental: 1
Daily Lutein/zeaxanthin supplementation with a meal
|
Dietary Supplement: lutein/zeaxanthin
daily supplementation of lutein and zeaxanthin at dose of 12 mg/day |
Placebo Comparator: 2 |
Dietary Supplement: placebo
placebo capsules with the same size and coating as those of lutein/zeaxanthin supplements without active ingredients |
- oxidative damage markers [ Time Frame: 3 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 55 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosed with moderately severe Alzheimer's disease

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00596024
United States, Oregon | |
Oregon Health and Science University | |
Portland, Oregon, United States, 97239 |
Principal Investigator: | Wei Wang, PhD | Oregon Health and Science University |
Responsible Party: | Oregon Health and Science University |
ClinicalTrials.gov Identifier: | NCT00596024 |
Other Study ID Numbers: |
LAD Alzheimer research fund |
First Posted: | January 16, 2008 Key Record Dates |
Last Update Posted: | August 12, 2019 |
Last Verified: | August 2019 |
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders |